METHOD OF TREATING PATIENTS WITH PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF CENTRAL NERVOUS SYSTEM Russian patent published in 2024 - IPC A61K39/395 A61K31/519 A61K36/24 A61K31/15 A61K31/4035 A61K31/17 A61K31/10 A61K31/66 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention relates to oncology and chemotherapy. Three-stage approach is followed for treating the patients diagnosed with primary diffuse large B-cell lymphoma of the central nervous system. First stage includes 4 courses of induction chemotherapy with the combined use of the preparation Lenalidomide by the oral administration from 2nd to 8th day of the cycle in dosage of 25 mg/day, of the preparation Rituximab by intravenous drop-by-drop introduction on the first day of the cycle of the preparation Rituximab in dosage of 375 mg/m², intravenous drop-by-drop introduction on 2nd day of the cycle of the preparation Methotrexate in dosage of 3,500 mg/m², intravenous bolus introduction on 2nd day of the cycle of the preparation Vincristine in dosage of 2 mg, oral administration of the preparation Procarbazine in dosage of 100 mg/m² from 2nd to 8th days of the cycle. Application of accompanying therapy, which includes water load, hypouricemic therapy, antiulcer therapy, anticoagulant therapy, antiemetic therapy, anticonvulsant therapy. Treatment involves the second stage of the therapy with the auto-HSCT in the air conditioning mode with the use of the preparations Carmustine, Busulfan, Cyclophosphamide with application of accompanying therapy, which includes water load, hypouricemic therapy, antiulcer therapy, anticoagulant therapy, antiemetic therapy, anticonvulsant therapy, hepatoprotective therapy. At the third stage, the therapy is carried out 3 months after the auto-HSCT of the maintenance therapy with PD-1 control point inhibitors, followed by a control examination every 3 months for 1 year, then every 6 months from 2nd year.

EFFECT: method enables reducing the risk of recurrent disease and increasing the survival rate, and also enables replacing the preparation Thiotepa in the therapy of the patients diagnosed with primary diffuse large B-cell lymphoma of the central nervous system.

38 cl, 7 ex, 7 tbl, 9 dwg